Immunmodulation und Tumorabwehr — Fantasien und Realitäten

  • A. L. de Weck
Conference paper

Zusammenfassung

Obwohl eine wesentliche Rolle des Immunsystems in der Abwehr gegen gewisse Tumore nicht bestritten werden kann, sind die Hoffnungen, die die Onkologie in die klassische Immunologie gesetzt hat, bis jetzt nicht völlig erfüllt worden. In der modernen Immunologie sind verschiedene naturwissenschaftlich fundierte Methoden entwickelt worden, um eine Tumorabwehr zu verstärken, bzw. zu steuern. In dieser Arbeit werden diese Methoden kurz zusammengefaßt und kritisch bewertet.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Baldwin RW, Byers VS, Pimon MV (1988) Monoclonal antibodies and immunoconjugates for cancer treatment. In: Pinedo HM, Longo DL, Chabner BA (Hrsg) Cancer chemotherapy and biological response modifiers. Annual 10. Elsevier, Amsterdam, pp 397–415Google Scholar
  2. 2.
    Clark JW (1988) Biological response modifiers. In: Pinedo HM, Longo DL, Chabner BA (Hrsg) Cancer chemotherapy and biological response modifiers. Annual 10. Elsevier, Amsterdam, pp 434–459Google Scholar
  3. 3.
    Dahinden CA, Zingg J, Maly FE, de Weck AL (1988) Leukotriene production in human neutrophils primed by recombinant human granulocyte-macrophage colonystimulating factor and stimulated with the complement component C5a and fMLP as second signals. J Exp Med 167:1281–1295PubMedCrossRefGoogle Scholar
  4. 4.
    Fidler IJ, Poste G (1981) Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Springer Semin Immunopathol 5:161Google Scholar
  5. 5.
    Herberman RB (1980) Immunologic reactivity of lymphoid cells in tumors. Contemp Top Immunobiol 10:161Google Scholar
  6. 6.
    Hellstrom I, Hellstrom KE (1983) Cell-mediated reactivity to human tumor-type associated antigens. Does it exist? J Biol Response Mod 2:310PubMedGoogle Scholar
  7. 7.
    Lotze MT, Matory YL, Rayner AA (1986) Clinical effects and toxicity of interleukin 2 in patients with cancer. Cancer 58:2764–2772PubMedCrossRefGoogle Scholar
  8. 8.
    Lotze MT, Rosenberg SA (1986) Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer. Immunobiology 172:420–437PubMedCrossRefGoogle Scholar
  9. 9.
    Oldham RK (1983) Monoclonal antibodies in cancer therapy. J Clin Oncol 1:582PubMedGoogle Scholar
  10. 10.
    Rosenberg SA (1984) Adoptive immunotherapy of cancer: Accomplishments and prospects. Cancer Treat Rep 68:233PubMedGoogle Scholar
  11. 11.
    Rosenberg SA, Lotze MT, Mulé JJ (1988) New approaches to the immunotherapy of cancer using interleukin 2. Ann Intern Med 108:853–864PubMedGoogle Scholar
  12. 12.
    Urba WJ, Longo DL (1988) Adoptive cellular therapy. In: Pinedo HM, Longo DL, Chabner BA (eds) Cancer chemotherapy and biological response modifiers. Annual 10. Elsevier, Amsterdam, pp 460–476Google Scholar
  13. 13.
    Vitetta ES, Uhr JW (1985) Immunotoxins. Annu. Rev Immunol 3:197PubMedCrossRefGoogle Scholar
  14. 14.
    Wagstaff J, Melief K (1988) Lymphokines and cytokines. In: Pinedo HM, Longo DL, Chabner BA (eds) Cancer Chemotherapy and biological response modifiers. Annual 10. Elsevier, Amsterdam, pp 416–433Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • A. L. de Weck
    • 1
  1. 1.Institut für klinische ImmunologieInselspitalBernSwitzerland

Personalised recommendations